Kiadis Pharma NV (FRA:K3P) EBIT per Share : €-2.08 (TTM As of Dec. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV EBIT per Share?

Kiadis Pharma NV's EBIT per Share for the six months ended in Dec. 2020 was €-1.55. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2020 was €-2.08.

During the past 3 years, the average EBIT per Share Growth Rate was 4.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was -5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Kiadis Pharma NV's EBIT per Share or its related term are showing as below:

FRA:K3P' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -52.7 Med: -31.4 Max: 4.8
Current: 4.8

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Kiadis Pharma NV was 4.80% per year. The lowest was -52.70% per year. And the median was -31.40% per year.

FRA:K3P's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.6 vs FRA:K3P: 4.80

Kiadis Pharma NV's EBIT for the six months ended in Dec. 2020 was €-62.13 Mil.

Kiadis Pharma NV EBIT per Share Historical Data

The historical data trend for Kiadis Pharma NV's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV EBIT per Share Chart

Kiadis Pharma NV Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EBIT per Share

Get a 7-Day Free Trial

-0.96

-0.99

-1.25

-1.77

-2.18

Kiadis Pharma NV Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
EBIT per Share	Get a 7-Day Free Trial											-0.61	-0.94	-0.84	-0.53	-1.55

Kiadis Pharma NV EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Kiadis Pharma NV's EBIT per Share for the fiscal year that ended in Dec. 2020 is calculated as

	EBIT per Share		(A: Dec. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-79.786	/	36.615
=	-2.18

Kiadis Pharma NV's EBIT per Share for the quarter that ended in Dec. 2020 is calculated as

	EBIT per Share		(Q: Dec. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-62.13	/	40.135
=	-1.55

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2020 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.08

Kiadis Pharma NV (FRA:K3P) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Kiadis Pharma NV EBIT per Share Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiadis Pharma NV (FRA:K3P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (FRA:K3P) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP

Website

https://www.kiadis.com

Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (FRA:K3P) Headlines

No Headlines